Bayer Avelox Skin Infection Indication "Approvable"; Needs More Safety Data
Executive Summary
Bayer's Avelox (moxifloxacin) is "approvable" for the treatment of uncomplicated skin and skin structure infections, FDA said in a Dec. 10 letter granting the antibiotic approval for three other indications.
You may also be interested in...
Glaxo Withdraws Raxar Following Seven Fatal Cardiovascular AEs
Glaxo Wellcome is withdrawing the quinolone antibiotic Raxar (grepafloxacin) from the worldwide markets after receiving a total of seven reports of cardiovascular event-related fatalities associated with use of the drug.
Bayer Avelox Cardiac Safety Studies Recommended By FDA Committee
Cardiac QT prolongation associated with Bayer's fluoroquinolone Avelox (moxifloxacin) should be evaluated in high risk patients, FDA's Anti-Infective Drugs Advisory Committee concluded Oct. 21.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011